Skip to main content
Premium Trial:

Request an Annual Quote

Adaptive Biotechnologies Lands $195M Series F Financing

NEW YORK (GenomeWeb) – Adaptive Biotechnologies today announced that it has completed a $195 million Series F financing round.

Matrix Capital Management led the round, which included other new investors Senator Investment Group, Tiger Management, Rock Springs Capital, and an unnamed large healthcare investor. The firm also raised money from existing investors Viking Global Investors, Casdin Capital, and Alexandria Real Estate Equities. 

The firm said it would use the proceeds to expand research and development, support commercialization of a biomarker identification technology for T-cell therapies, and fund regulatory submissions.

Adaptive Biotechnologies is creating a platform for next-generation sequencing of T cell and B cell receptors and a database for immune biomarkers to identify targets for use in immunotherapies.

In January, Adaptive Biotechnologies acquired immune sequencing firm Sequenta. The Fred Hutchinson Cancer Research Center spinout had previously raised a total of $120 million, with at least $105 million from Viking Global.

The Scan

RNA Editing in Octopuses Seems to Help Acclimation to Shifts in Water Temperature

A paper in Cell reports that octopuses use RNA editing to help them adjust to different water temperatures.

Topical Compound to Block EGFR Inhibitors May Ease Skin Toxicities, Study Finds

A topical treatment described in Science Translational Medicine may limit skin toxicities seen with EGFR inhibitor therapy.

Dozen Genetic Loci Linked to Preeclampsia Risk in New GWAS

An analysis of genome-wide association study data in JAMA Cardiology finds genetic loci linked to preeclampsia that have ties to blood pressure.

Cancer Survival Linked to Mutational Burden in Pan-Cancer Analysis

A pan-cancer paper appearing in JCO Precision Oncology suggests tumor mutation patterns provide clues for predicting cancer survival that are independent of other prognostic factors.